Stockpolly
Search
Delisting risk
ENVB · NASDAQ · Biotechnology

Enveric Biosciences (ENVB)

Develops non-hallucinogenic neuroplastogenic medicines for psychiatric and neurological disorders.

$1.44
Pre-market+0.02 (+1.77%)
At close$1.42(+3.28%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
322223222223
Research & development110111110001
212112111212
General & administrative002000001012
Operating income−3−2−2−2−2−3−2−3−2−2−2−3
1−10000000000
Interest income000000000000
Interest expense00—000000000
Other non-operating income−110000000000
Income before tax−3−3−2−2−2−3−2−3−2−2−2−3
Income tax expense000000000000
Net income from continuing operations−3−3−2−2−2−3−2−3−2−2−2−3
Net income−3−3−2−2−2−3−2−3−2−2−2−3
EPS, basic−$15.60−$33.51−$21.00−$16.08−$43.08−$69.84−$14,584.44−$11.64−$10.81−$3.81−$1.08−$0.76
EPS, diluted−$27.53−$33.51−$21.00−$16.08−$17.76−$57.84−$14,584.44−$11.64−$10.81−$3.81−$1.08−$0.76
Weighted average shares, basic000000000124
Weighted average shares, diluted000000000124
EBITDA−3−3−2−2−2−3−2−2−2−2−2−3
Depreciation & amortization000000000000
EBIT−3−3−2−2−2−3−2−3−2−2−2−3